Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $183000.0.

  • Kyntra Bio's Depreciation & Amortization (CF) fell 7493.15% to $183000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 7474.26%. This contributed to the annual value of $2.7 million for FY2024, which is 7211.6% down from last year.
  • Latest data reveals that Kyntra Bio reported Depreciation & Amortization (CF) of $183000.0 as of Q3 2025, which was down 7493.15% from $212000.0 recorded in Q2 2025.
  • Kyntra Bio's 5-year Depreciation & Amortization (CF) high stood at $2.7 million for Q1 2021, and its period low was $183000.0 during Q3 2025.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $2.5 million (2021), whereas its average is $1.7 million.
  • Per our database at Business Quant, Kyntra Bio's Depreciation & Amortization (CF) surged by 378.4% in 2023 and then crashed by 8166.22% in 2024.
  • Quarter analysis of 5 years shows Kyntra Bio's Depreciation & Amortization (CF) stood at $2.5 million in 2021, then increased by 1.25% to $2.5 million in 2022, then decreased by 25.82% to $1.9 million in 2023, then tumbled by 81.66% to $342000.0 in 2024, then crashed by 46.49% to $183000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $183000.0 for Q3 2025, versus $212000.0 for Q2 2025 and $318000.0 for Q1 2025.